Ontology highlight
ABSTRACT:
SUBMITTER: Ahamadi M
PROVIDER: S-EPMC5270291 | biostudies-literature | 2017 Jan
REPOSITORIES: biostudies-literature
Ahamadi M M Freshwater T T Prohn M M Li C H CH de Alwis D P DP de Greef R R Elassaiss-Schaap J J Kondic A A Stone J A JA
CPT: pharmacometrics & systems pharmacology 20161114 1
Pembrolizumab, a potent antibody against programmed death 1 (PD-1) receptor, has shown robust antitumor activity and manageable safety in patients with advanced solid tumors. Its pharmacokinetic (PK) properties were analyzed with population PK modeling using pooled data from the KEYNOTE-001, -002, and -006 studies of patients with advanced melanoma, non-small cell lung cancer (NSCLC), and other solid tumor types. Pembrolizumab clearance was low and the volume of distribution small, as is typical ...[more]